CD274 and sarcoma: Emerging immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, and targeted therapies have shown potential efficacy in various sarcoma subtypes, offering new treatment options for advanced soft tissue sarcoma patients (21).